Anupam Rasayan India Limited — PPTs, 14-02-2026: Investor Presentation

Anupam Rasayan (ANURAS) posted strong Q3 & 9M FY26 financial results. Consolidated revenue for the nine-month period surged 84% YoY to ₹1,729.7 Cr, with PAT up 71% to ₹166.2 Cr. Quarterly consolidated revenue grew 31% to ₹512.4 Cr, and PAT rose 12% to ₹60.6 Cr, fueled by new molecule ramp-ups and traction in life sciences & performance materials.

A key strategic development is the acquisition of US-based Jayhawk Fine Chemicals for ~$134M. This move expands ANURAS's global footprint, boosts custom synthesis capabilities, and strengthens access to North American innovator markets.

Growth drivers include expanding its Pharma & Polymer portfolios, executing signed contracts, and deepening its fluorination chemistry platform. Management sees a clear path to sustained growth, building a diversified, multi-geography platform in specialty & high-purity chemicals.